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Advances in genome sequencing have resulted in the identification of the causes for numerous rare diseases. However, many
cases remain unsolved with standard molecular analyses. We describe a family presenting with a phenotype resembling
inherited thrombocytopenia 2 (THC2). THC2 is generally caused by single nucleotide variants that prevent silencing of
ANKRD26 expression during hematopoietic differentiation. Short-read whole-exome and genome sequencing approaches were
unable to identify a causal variant in this family. Using long-read whole-genome sequencing, a large complex structural variant
involving a paired-duplication inversion was identified. Through functional studies, we show that this structural variant
results in a pathogenic gain-of-function WAC-ANKRD26 fusion transcript. Our findings illustrate how complex structural
variants that may be missed by conventional genome sequencing approaches can cause human disease.
Introduction
Recent progress in genome sequencing has enabled insights
into the cause of a range of rare diseases, including numerous
congenital blood disorders (Hartley et al., 2020; Liggett and
Sankaran, 2020; Thaventhiran et al., 2020; Turro et al., 2020).
Despite these important technological and computational ad-
vances, a substantial subset of cases remains unsolved. Com-
plex structural variants (SVs) that alter the arrangement of
large segments of the genome can be challenging to identify,
especially with the use of conventional short-read sequencing
approaches that are commonly employed for whole-exome or
genome sequencing (Eichler, 2019). Moreover, the functional
impact of specific germline SVs often remains poorly under-
stood, particularly when these variants result in fusion tran-
scripts or cause complex alterations beyond unambiguous loss-
of-function alleles in specific genes (Eichler, 2019; Spielmann
et al., 2018).
Here, we illustrate the specific challenges that can arise in
identifying and characterizing a complex SV. We study a
multigenerational family impacted by congenital thrombo-
cytopenia, resembling inherited thrombocytopenia 2 (THC2;
Online Mendelian Inheritance in Man accession no. 188000;
Noris et al., 2011; Pippucci et al., 2011; Tan et al., 2020; Turro
et al., 2020), which is typically caused by single nucleotide
variants (SNVs) that de-repress ANKRD26 expression during
megakaryocytic differentiation (Bluteau et al., 2014; Marconi
et al., 2017). THC2 is generally characterized by thrombocy-
topenia accompanied by altered hematopoiesis and predis-
position to myeloid malignancies. Using long-read sequencing
approaches, we assemble and fully resolve a complex SV af-
fecting the gene implicated in THC2, ANKRD26. In contrast to
previously described THC2 cases, this SV produces a unique
fusion transcript between the first exon of WAC and exons
10–34 of ANKRD26. We demonstrate how this gene fusion acts
through a gain-of-function mechanism to cause disease. More
broadly, we provide an example of how commonly employed
clinical variant detection and sequencing approaches can be
blind to the detection of cryptic SVs that can cause human
diseases.
Results and discussion
In the course of our studies of genetic blood disorders, we en-
countered a three-generation family where multiple members
were impacted by thrombocytopenia (Fig. 1 A and Table 1). In-
dividual I-2 had first come to clinical attention when she was 8
yr old and had developed petechiae. A low platelet count was
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noted at that time. At the age of 21 yr, given ongoing thrombo-
cytopenia, a bone marrow biopsy and aspirate were undertaken,
and a presumptive diagnosis of immune thrombocytopenia was
made, given the presence of abundant megakaryocytes. Platelets
were provided before surgeries in this individual; otherwise, no
severe bleeding was noted. Two daughters of this individual, II-2
and II-3, were also found to be thrombocytopenic with easy
bruising, epistaxis, and menorrhagia. However, an underlying
etiology remained unidentified. Individual III-1 (the daughter of
II-2) came to clinical attention for thrombocytopenia in the
Figure 1. A large paired-duplication inversion SV identified as the cause of inherited thrombocytopenia. (A) Pedigree of a three-generation family
affected with inherited thrombocytopenia. (B) Representative image of a peripheral blood smear from individual III-1, demonstrating severe thrombocytopenia
with few platelets exhibiting normal granularity (red arrows). Scale bar: 10 µm. (C) Schematic of the genetic workup performed to identify the causal variant in
this family, highlighting conventional clinical analyses (blue) versus additional approaches (red) needed to resolve this case. (D) The wild-type locus versus a
local assembly of the paired-duplication inversion highlighting duplicated regions (greens), inverted segments (angular brackets), and microhomology regions
(red and blue arrow heads) and with genes along each assembly (pink arrows denoting genes that are affected by the SV). ICE, Inosine Chemical Erasing
Sequencing.
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setting of a known family history, and a workup was initiated at
our institution (Fig. 1 B). As further studies were performed, all
members of this family and the children of II-3 were ascertained
(Table 1). While platelet counts in this family were relatively
consistent within individuals at multiple time points, the range
of thrombocytopenia between family members was found to be
fairly broad, consistent with previously reported cases of THC2.
Individuals I-2, II-2, II-3, and III-1 presented with more severe
thrombocytopenia and were more symptomatic (Table 1),
whereas individuals III-5, III-6, and III-7 were found to have
mild to moderate thrombocytopenia and were reported to have
few bleeding-related complications. We note that there appears
to be age-dependent variation in platelet count in this family,
suggesting that some of the variation may be the result of age-
dependent changes in hematopoiesis. Analysis of complete
blood counts and peripheral blood smears of affected in-
dividuals demonstrated normal platelet size, volume, and
granularity. Beyond the thrombocytopenia, no other recurrent
hematologic or other medical problems were noted.
SV identification
Based on the clinical presentation of individual III-1 and other
family members, targeted Sanger sequencing of RUNX1, GATA1,
MPL, and ANKRD26 was performed, but no pathogenic or other
relevant variants were identified. Given the lack of identified
mutations in this family, whole-exome sequencing of affected
individuals II-2, III-1, III-3, and III-4 was performed, but no SNVs
or small insertions/deletions (indels) were identified that ap-
propriately segregated and appeared relevant to the observed
blood disorder (Fig. 1 A). Additional analysis by short-read
whole-genome sequencing (WGS), as is employed in standard
clinical diagnostic approaches, also failed to identify other pu-
tative causal variants (Stanley et al., 2020; Ulirsch et al., 2018).
Thorough reanalysis of the short-read exome sequencing data
suggested increased sequencing coverage across a subset of
exons in the ANKRD26 gene, which was also noted in the short-
read genome sequencing data obtained. However, these ap-
proaches did not clearly elucidate the nature of this complex SV.
Therefore, by leveraging the precision of short-read genome
sequencing with additional information provided by long-read
genome sequencing of a trio within the larger pedigree (II-1, II-2,
III-4), the duplication was determined to span exons 10–20 of
ANKRD26 and, more importantly, to be part of a larger complex
SV composed of two duplications flanking a large inversion
(paired-duplication inversion). These complementary technol-
ogies allowed for this SV to be precisely assembled (Fig. 1, C and
D). Inspection of each breakpoint revealed microhomology be-
tween Alu repeats consisting of 45 and 2 bp, which is consistent
with previous findings for paired-duplication inversions
(Fig. 1 D; Brand et al., 2015). Short-read WGS was performed on
all remaining affected family members, and breakpoints were
found to be stable across all individuals over multiple gen-
erations. A PCR-based genotyping assay to assess the presence of
this SV was developed and validated in affected family members
and confirmed that all clinically unaffected familymemberswho
were not sequenced (e.g., III-2) did not carry this SV (Fig. S1, A
and B). We found that this SV segregated appropriately in all
family members with a logarithm of the odds score of 2.71 (nine
individuals showing nonrecombinant phenotypes), suggesting
that the cosegregation of this SV and thrombocytopenia had a <1
in 500 probability of being due to chance.
Characterization of molecular pathogenesis of the SV
To date, all pathogenic variants causing THC2 have been found
in the proximal promoter of ANKRD26, a region that is bound by
the key hematopoietic transcription factors RUNX1 and FLI1
(Fig. 2 A; Marconi et al., 2017). Binding of these transcription
factors causes silencing of the ANKRD26 gene, thereby limiting
downstream thrombopoietin (TPO) signaling and enabling ef-
fective megakaryocytic maturation and proplatelet formation.
The pathogenic variants identified previously prevent silencing
of ANKRD26 in megakaryocytes, where it is normally repressed
(Fig. 2 B; Bluteau et al., 2014). The SV present in this family,
despite being large in size, only results in alterations in the
structure of ANKRD26 and the WAC genes, with the WAC gene
retaining a completely intact reading frame (Fig. 1 D). Impor-
tantly, sequencing analysis confirmed the absence of pathogenic
ANKRD26 promoter variants in affected familymembers (Fig. 1 D
and Fig. S2 A). Interestingly, we found that this SV caused the
proximal promoter and exon 1 of theWAC gene to be juxtaposed,
with exons 10–34 of ANKRD26 resulting in an open reading
frame that might enable transcription of a fusion between exon
1 ofWAC and ANKRD26. Notably, the expression ofWACmRNA is
ubiquitous within the hematopoietic system and occurs at much
higher levels than ANKRD26, suggesting a mechanism by which
overexpression of an N-terminally truncated ANKRD26 could be
achieved (Fig. 2 B). To directly assess the altered transcription oc-
curring due to this SV, we performed RNA sequencing on periph-
eral bloodmononuclear cells (PBMCs) from three affected probands
(I-2, II-2, and II-3) and three unrelated healthy controls. Alignment
of these data demonstrated large numbers of both reads where a
single read spanned WAC exon 1 and ANKRD26 exon 10 as well as
paired reads wherein one read mapped to WAC and the other to
ANKRD26 (Fig. 2 C). These events were only detected in affected
individuals, supporting a transcript fusion occurring due to the
paired-duplication inversion (Fig. 2 C). Concomitantly, we noted
upregulation of ANKRD26mRNA levels (∼50-fold) in the PBMCs of
individuals with the SV compared with the controls, which was
specific to exons that are part of the WAC-ANKRD26 fusion we
identified, but no significant change in expression for any other
gene that was contained within or near to the SV (Fig. 2, D and E).
The additional changes in gene expression likely reflect changes in
the peripheral blood composition of affected individuals, who are
thrombocytopenic, compared with controls, as demonstrated by
reduced platelet-associated gene signatures and concomitant upre-
gulation of myeloid cell–associated signatures (Fig. S2, C and D).
Therefore, we can directly demonstrate that this pathogenic SV
leads to fusion of theWAC promoter and exon 1 with exons 10–34 of
ANKRD26, resulting in overexpression of the ANKRD26 C-terminal
encoding region.
Functional analysis of fusion transcript activity
The resultant fusion transcripts were challenging to fully re-
solve, as multiple isoforms of both WAC and ANKRD26 could be
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involved. Most potential fusion transcripts detected through
RNA sequencing fromWAC to ANKRD26were predicted to be out
of frame for effective translation as a fusion. However, one
noncanonical isoform of WAC (WAC-221) would form an in-
frame fusion with exons 10–34 of ANKRD26 (Fig. 3 A). The
most likely ANKRD26 isoform participating in this fusion is
ANKRD26-202 based on a skipped exon with decreased coverage
in the RNA sequencing data (Fig. 2 C, red arrow). Concomitantly,
the fusion of all WAC transcripts with exons 10–34 of ANKRD26
would also enable translation of a truncated form of ANKRD26
starting from a methionine located in exon 11 that would remove
all ankyrin repeats but retain the coiled-coil domain (Fig. 3, A and
B). Upon exogenous expression of either the full-length ANKRD26,
exon 11 methionine initiating ANKRD26 (herein exon 11+), or the
WAC-ANKRD26 fusion cDNAs in HEK 293T cells, robust protein
expression could be detected from the full-length and truncated
exon 11+ ANKRD26 but not from the fusion transcript, showing
that the fusion transcript was unlikely to result in a stable protein
that could have pathogenic consequences (Fig. 3 C).
We then sought to assess the impact of full-length or the
truncated exon 11+ ANKRD26 in the physiologically relevant
context of human hematopoiesis. We therefore introduced len-
tiviruses encoding these cDNAs into primary human CD34+
hematopoietic stem and progenitor cells (HSPCs) from healthy
donors. We cultured the cells over 4 d in conditions that main-
tain the HSPCs. Increased ANKRD26 expression was confirmed
by RT-PCR fromHSPCs sorted for GFP at 96 h after transduction
(Fig. 3 D). We then starved and restimulated cells with throm-
bopoietin (Gibbs et al., 2011). Remarkably, we noted significantly
increased levels of ERK phosphorylation with either the over-
expression of full-length or the exon 11+–truncated ANKRD26 in
HSPCs, whereas this was not the case with the control empty
vector (Fig. 3, E–H). This finding directly demonstrates that
increased and deregulated expression of a truncated form of
ANKRD26 is sufficient to result in increased MAPK activation
downstream of the TPO receptor and specifically in a larger
fraction of HSPCs than is observed normally (Gibbs et al., 2011;
Kaushansky, 2006).
Figure 2. The identified SV causes a partial transcript fusion of WAC and ANKRD26 genes, leading to overexpression of a functional ANKRD26
fragment. (A) Illustration of previously described ANKRD26 promoter region variants, which lead to de-repression of ANKRD26 and are either causal or as-
sociated with THC2. (B) Expression (log2-normalized counts per million [cpm]) of the ANKRD26 and WAC genes throughout hematopoietic lineages highlights
the robust ubiquitous expression of the WAC versus the regulated and lower expression of ANKRD26. (C) Sashimi plot of RNA sequencing transcriptomes of
pooled controls versus affected individuals, highlighting the existence of aWAC-ANKRD26 fusion transcript that is only present in affected individuals (top; red
arc). (D) Volcano plot showing that ANKRD26 is one of the most overexpressed genes in affected individuals versus controls, whereas other genes in this locus
are unchanged (bottom left; red). (E) Bar plot of ANKRD26 and WAC expression, highlighting the exons involved and not involved in the SV, shows that
overexpression is due to the exons that are part of the WAC-ANKRD26 fusion. adj. p-val, adjusted P value; aff., affected; FC, fold change; unaff., unaffected.
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Conclusions
Here, we describe a multigenerational family affected with a
phenotype resembling THC2 characterized by congenital
thrombocytopenia (Pippucci et al., 2011). We identify the causal
variant as a paired-duplication inversion affecting a large
region involving 1.3 Mb on chromosome 10 that is significantly
associated with the observed hematologic phenotype. Through
molecular studies, we show that this complex SV leads to a
previously undescribed WAC-ANKRD26 fusion transcript that
demonstrates gain-of-function activity in functional assays
Figure 3. A truncated region of ANKRD26 retains ANKRD26 functions. (A) Gene models showing full-length ANKRD26, the in-frame WAC-ANKRD26
fusion, and the 59-truncated ANKRD26 starting from Met453. (B) Protein models of the stably expressed full-length and N-terminally truncated ANKRD26.
(C) Exogenous expression of full-length ANKRD26, exon 11+ cDNA, but not WAC-ANKRD26 fusion transcript can be detected, suggesting that the fusion
transcript does not result in a stable protein. Protein expression levels of ANKRD26 by Western blot (WB) from whole-cell lysates of HEK 293T cells shown by
probing for N- and C-terminal ANKRD26 epitopes. (D) RT-PCR analysis of ANKRD26 mRNA from human HSPC sorted for GFP at 96 h after transduction with
full-length ANKRD26 and exon 11+ cDNA confirms overexpression of ANKRD26 by 14.8 ± 0.88 and 14.79 ± 1.77, respectively. Data were normalized to the ACTB
transcript level and represent mean ± SD of triplicates. (E) A representative replicate showing ERK phosphorylation assessed by flow cytometry in primary
human HSPCs 96 h after lentiviral transduction with the empty control vector, full-length ANKRD26, or ANKRD26 exon 11+. (F) A bar plot showing quantification
of three biological replicates of the percentage of pERK+ of GFP+ (successfully infected) cells (mean ± SD of triplicates shown). (G) A bar plot showing
quantification of three biological replicates of the pERKmean fluorescence intensity (MFI) among GFP+ cells (mean ± SD of triplicates shown). (H) Representative
histograms illustrating MFI of pERK within the GFP+ gate are shown for serum-starved HSPCs that were stimulated with TPO. A significant increase was noted
for both full-length ANKRD26 and ANKRD26 exon 11+. P values were calculated by one-way ANOVA test followed by Dunnet’s test (***, P < 0.001).
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through initiation from an internal methionine in exon 11 of
ANKRD26. Conventional WGS approaches can harbor a “blind
spot” for complex SVs (Sedlazeck et al., 2018). This study illu-
minates the complexity in readily identifying, assembling, and
defining pathogenic mechanisms for germline SVs that cause
human disease. Moreover, only by RNA sequencing was it
possible to prove the existence of, not just potential for, this
fusion of WAC and ANKRD26 that underlies the pathogenic
mechanisms in the family. This emphasizes the need to con-
sider such emerging approaches for cases unsolved using con-
ventional WGS and annotation approaches (Eichler, 2019).
One important implication of this work is that it provides
new insights into the regions of ANKRD26 that are necessary
and sufficient for its pathogenic gain-of-function activity
through juxtaposition with the highly active promoter of theWAC
gene. Importantly, the truncated form of ANKRD26 that we find
through this gene fusion removes the N-terminal ankyrin repeats
while retaining the coiled-coil domain of this protein (Fig. 3 B). It
is likely that further studies that build off these insights may lead
to the identification of other pathogenic mechanisms that can
impact ANKRD26 expression and thereby alter hematopoiesis to
cause thrombocytopenia and increased risk for myeloid malig-
nancies. Indeed, many current screening approaches for germline
or acquired ANKRD26mutations in hematologic malignancies that
focus on SNVs in the promoter region may miss potential patho-
genic mutations (Kuo et al., 2017; Turro et al., 2020).
We also emphasize the key role that functional characteri-
zation has in delineating pathogenic mechanisms resulting from
these SVs. Although the pathogenic mechanisms for a variety of
complex SVs may result from loss-of-function alleles, such
complex SVs can alter genome topology to cause unique changes
in gene expression (Spielmann et al., 2018). Here, we provide an
example of a gain-of-function fusion transcript created as a re-
sult of this complex SV. We highlight the necessity of comple-
mentary functional assays to dissect pathogenic mechanisms
and emphasize the challenges ahead as a larger number of such
complex SVs are recognized, assembled, and found to be asso-
ciated with disease. Indeed, as our appreciation for genome
variation in health and disease grows, our understanding of the
enumerable mechanisms that can disrupt fundamental biologi-
cal processes will continue to grow. Moreover, as advances in
sequencing technologies enable identification of previously un-
solved disease-associated variation, we will continue to highlight
blind spots inherent in genetic technologies that currently mark
the standard of clinical care.
Materials and methods
Study approval
This study was approved by the institutional review board at
Boston Children’s Hospital, and informed consent was obtained
for all individuals described. Clinical testing for pathogenic
variants in RUNX1, MPL, GATA1, and ANKRD26 was performed.
Whole-exome sequencing
Whole-exome sequencing was performed with an Illumina
Nextera exome capture (∼38-Mb target) and sequenced (150-bp
paired reads) to cover >80% of targets at 20× and with a mean
target coverage of >100×. Exome sequencing data were pro-
cessed through a Picard-based pipeline, and mapping was done
using the Burrows–Wheeler aligner to human genome build
38 (NCBI Assembly accession no. GRCh38.p13). Variants were
called using Genome Analysis Toolkit (GATK) HaplotypeCaller
package version 3.5. Putative copy number variations were
called using the tool gCNV, which leverages the combined
exomes of the larger Broad Institute of Massachusetts Institute
of Technology and Harvard Center for Mendelian Genomics
cohort.
Short-read WGS
WGS and data processing were performed by PCR-free prepa-
ration of sample DNA (350 ng input at >2 ng/μl) using Illumina
HiSeq X Ten v2 chemistry (Abdulhay et al., 2019). Libraries are
sequenced to a mean target coverage of >30×. WGS data were
processed through a pipeline based on Picard, using base quality
score recalibration and local realignment at known indels.
The Burrows–Wheeler aligner was used for mapping reads to
GRCh38. SNVs and indels are jointly called across all samples
using the GATK HaplotypeCaller package version 4.0. Default
filters were applied to SNV and indel calls using the GATK
Variant Quality Score Recalibration approach. Annotation was
performed using Variant Effect Predictor. SVs were evaluated
with the tools Delly, Manta, and Smoove.
Short-read sequencing variant analysis
SNVs and indels were evaluated collaboratively using the tools
seqr and gemini under a dominant inheritance model for both
whole-exome and whole-genome variants. Variants with ex-
tremely low allele counts (<5) in the Genome Aggregation
Database cohort were prioritized based on the rarity of the
phenotype as well as the clinical prescreening for common
causes of inherited thrombocytopenia. SVs were prioritized by
being called by all three tools (Delly, Manta, and Smoove) and
in proximity to known thrombocytopenia-associated genes.
Long-read WGS
Long-read sequencing was performed using the Pacific Bio-
sciences (PacBio) circular consensus sequencing (CCS) protocol.
Briefly, for library preparation, 5 μg of high molecular weight
genomic DNA (>50% of fragments ≥40 kb) was sheared to ∼10
kb using theMegaruptor 3 (B06010003; Diagenode), followed by
DNA repair and ligation of PacBio adapters using the SMRTbell
Template Prep Kit v1.0 (100-991-900). Libraries were then size
selected for 10 kb ± 20% using the SageELF with 0.75% agarose
cassettes (Sage Science). Following quantificationwith the Qubit
dsDNA High Sensitivity Assay Kit (Q32854; Thermo Fisher Sci-
entific), libraries were diluted to 50 pM per single molecule,
real-time (SMRT) cell, hybridized with PacBio v2 sequencing
primer, and bound with SMRT sequencing polymerase using
Sequel II Binding Kit 1.0 (101-731-100). CCS sequencing was
performed on the Sequel II instrument using 8M SMRT Cells
(101-389-001) and Sequel II Sequencing 1.0 Kit (101-717-200),
with a 2-h preextension time and 30-h movie time per
SMRT cell. Initial quality filtering, base calling, and adapter
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marking were performed automatically on board the Sequel II to
generate an initial raw “subreads.bam” file.
CCS reads were generated using CCS software v.3.4.1 from
PacBio (https://github.com/PacificBiosciences/ccs) with param-
eters “–minPasses 3–minPredictedAccuracy 0.99–maxLength
21000,” Reads were mapped to the GRCh38 human reference
genome without alternate loci. CCS reads were mapped using
minimap2-2.17 (r941) with parameters “-ayYL–MD–eqx -x
asm20.” SV calls were generated using pbsv v.2.2.0 (https://
github.com/PacificBiosciences/pbsv) on minimap2 CCS read
alignments. The pbsv discover stage was run on the whole ge-
nome using tandem repeat annotations supplied via the
“–tandem-repeats” argument. The pbsv call stage was run on the
full genome. The complete SV was locally assembled through
manual analysis of short-read sequencing data and long-read
sequencing data by evaluating split, soft-clipped, and discor-
dant reads using both Samtools and the Integrated Genomics
Viewer.
Analysis of RNA sequencing data from peripheral blood
To assess for altered transcripts produced by the SV in affected
individuals or in healthy controls, RNA was obtained from iso-
lated PBMCs and subjected to full-length RNA sequencing
analysis. For this, 4–5-ml samples of peripheral blood were ob-
tained by venipuncture, and PBMCs were isolated via density
gradient centrifugation using SeptMate columns (STEMCELL
Technologies, Inc.), resulting in PBMC yields ranging from 1.5 to
3 × 107 cells per individual. RNA was isolated using an RNeasy
Micro Kit (QIAGEN) according to the manufacturer’s in-
structions. An on-column DNase digestion was performed be-
fore RNA was quantified using a Qubit RNA HS Assay Kit
(Invitrogen). Approximately 10 ng of RNA was used as input to
a modified SMART-seq2 protocol, and after RT, 10 cycles of PCR
were used to amplify the transcriptome library (Abdulhay
et al., 2019; Ludwig et al., 2019; Picelli et al., 2014). Quality of
whole-transcriptome libraries was validated using a High
Sensitivity DNA Chip Run on a Bioanalyzer 2100 system (Agi-
lent) followed by library preparation using the Nextera XT kit
(Illumina) and custom index primers according to the manu-
facturer’s instructions. Final libraries were quantified using a
Qubit dsDNA HS Assay Kit (Invitrogen) and a High Sensitivity
DNA Chip Run on a Bioanalyzer 2100 system (Agilent). All li-
braries were sequenced using Nextseq High Output Cartridge
Kits and a Nextseq 500 sequencer (Illumina).
For differential expression, raw fastq files were aligned to
the GRCh38 human reference genome without alternate loci with
genes defined by GENCODE V22 using STAR 2.7.2b. STARwas run
using the settings outFilterMultimapNmax 1–outFilterMatchNmin
35–twopassMode Basic. Gene count matrices were also generated
by STAR using the setting quantMode GeneCounts. Differential
expression was performed using R-based DEseq2 method, and
statistical significance was determined by independent hy-
pothesis weighting (P < 0.01). Gene fusions were detected
using the tool STAR fusion using the online tool cloud com-
puting platform Terra with all default parameters. Details are
available at https://github.com/STAR-Fusion/STAR-Fusion/
wiki/Terra. Gene fusions were plotted using the R package
Gviz. For detailed inspection of potential fusion transcripts,
all cases and all controls were pooled and visualized in Inte-
grated Genomics Viewer.
Hematopoietic expression analyses
Hematopoietic lineage RNA sequencing raw data were obtained
from the Gene Expression Omnibus (accession nos. GSE74246,
GSE58202, GSE96811, and GSE107011) for all cell lineages except
megakaryocytes, which were obtained prequantified from the
Blueprint Epigenomics Consortium (Stunnenberg et al., 2016).
Raw data were aligned and quantified in order to facilitate
downstream merging. Downstream of this protocol, expected
count data from RSEM was quantile normalized. Counts were
summed per cell type after normalization to prevent over-
weighting of more deeply sequenced samples/donors. Cells were
colored in accordance with the log2 counts per million of the
ANKRD26 and WAC genes.
Cell culture and lentiviral transduction
cDNA encoding full-length or truncated exon11+ ANKRD26 and a
WAC-ANKRD26 fusion starting from exon 10 of ANKRD26 were
cloned into the HMD lentiviral backbone. For production of
lentiviruses, the appropriate viral packaging and genomic vec-
tors were introduced into HEK 293T cells with calcium phos-
phate transfection. Viral supernatants were collected 48 h after
transfection. To examine the activity of the fusion transcript-
encoded cDNAs, overexpression in HSPCs was performed by
transduction of relevant constructs at a multiplicity of infection of
50. HSPCs were cultured for 5 d after transduction in serum-free
StemSpan II medium (STEMCELL Technologies) supplemented
with CC100 cytokine cocktail (STEMCELL Technologies), 50 ng/
ml TPO (PeproTech), and 35 nM UM171 (Bao et al., 2020). To as-
sess for effects upon signaling activity downstream of the TPO
receptor, 96 h after transduction cells were serum starved for 2 h
followed by stimulation with TPO at 50 ng/ml for 15 min and
subjected to downstream analysis.
Flow cytometry
After 96 h in culture, HSPCs were fixed and permeabilized ac-
cording to manufacturer’s instructions and analyzed with in-
tracellular flow cytometry using a Phosphoflow kit (BD Biosciences).
Cells were stained for 60min with pERK1/2 (Thr202/Tyr204) Alexa
Fluor 647–conjugated antibodies (BD Biosciences) and subjected to
flow cytometry. Flow cytometry data were analyzed with FlowJo
software (version 10.6.1).
Western blotting
Protein expression for all constructs was examined after trans-
fection into HEK 293T and HeLa cells. Cells were harvested,
washed twice with ice-cold PBS, resuspended in radioimmuno-
assay lysis buffer (50mMTris-HCl at pH 7.4, 150mMNaCl, 0.1%
SDS, 1% NP-40, 0.25% sodium deoxycholate, 1 mM dithiothrei-
tol) supplemented with 1× Complete Protease Inhibitor Cocktail
(Roche) and 1× PhosSTOP (Roche). After centrifugation at
14,000 rpm for 10 min at 4°C to remove cellular debris, whole-
cell lysates were denatured at 90°C for 10 min. Equal amounts of
protein were separated by SDS gel electrophoresis using 4–12%
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polyacrylamide gels (Bio-Rad). Subsequently, proteins were
transferred onto a polyvinylidene fluoride membrane. Mem-
branes were incubated with blocking buffer (LI-COR Bio-
sciences) and probed with rabbit polyclonal antibody to
N-terminal ANKRD26 (ab183846; Abcam), rabbit polyclonal
antibody to C-terminal ANKRD26 (ab86780; Abcam), mouse
monoclonal antibody to phospho-p44/42 MAPK (#9106; Cell
Signaling Technology), rabbit monoclonal antibody to p44/42
MAPK (#9102; Cell Signaling Technology), and mouse mono-
clonal antibody to actin (sc-47778; Santa Cruz Biotechnology) all
at a 1:1,000 dilution overnight at 4°C. Membranes were then
washed with PBS, incubated with secondary antibodies (IRDye
Secondary Antibodies; LI-COR Biosciences), and analyzed using
the LI-COR Odyssey imaging system.
Data availability
Raw fastq and processed count matrices for the RNA sequencing
data are available at Genome Expression Omnibus (accession no.
GSE166409). The genome and exome sequencing data files and
associated metadata are available under database of Genotypes and
Phenotypes accession no. phs001272 at the Genomic Analysis, Vi-
sualization, and Informatics Lab-space.
Online supplemental material
Fig. S1 shows the PCR strategy that was used to confirm the
absence of the SV in individual III-2. Fig. S2 shows sequencing
data illustrating the absence of ANKRD26 promoter variants in
affected individuals and gene expression profiles demonstrating
that ANKRD26 overexpression leads to a suppression of platelet
gene signatures and upregulation of core myeloid leukocyte
genes in affected versus unaffected controls.
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Spielmann, M., D.G. Lupiáñez, and S. Mundlos. 2018. Structural variation in
the 3D genome. Nat. Rev. Genet. 19:453–467. https://doi.org/10.1038/
s41576-018-0007-0
Stanley, K.E., J. Giordano, V. Thorsten, C. Buchovecky, A. Thomas, M. Ga-
napathi, J. Liao, A.V. Dharmadhikari, A. Revah-Politi, M. Ernst, et al.
2020. Causal genetic variants in stillbirth. N. Engl. J. Med. 383:1107–1116.
https://doi.org/10.1056/NEJMoa1908753
Stunnenberg, H.G., and M. Hirst. International Human Epigenome Consor-
tium. 2016. The International Human Epigenome Consortium: A blue-
print for scientific collaboration and discovery. Cell. 167:1145–1149.
https://doi.org/10.1016/j.cell.2016.11.007
Tan, C., L. Dai, Z. Chen, W. Yang, Y. Wang, C. Zeng, Z. Xiang, X. Wang, X.
Zhang, Q. Ran, et al. 2020. A rare big Chinese family with thrombo-
cytopenia 2: a case report and literature review. Front. Genet. 11:340.
https://doi.org/10.3389/fgene.2020.00340
Thaventhiran, J.E.D., H. Lango Allen, O.S. Burren, W. Rae, D. Greene, E.
Staples, Z. Zhang, J.H.R. Farmery, I. Simeoni, E. Rivers, et al. Primary
Immunodeficiency Consortium for the NIHR Bioresource. 2020.
Whole-genome sequencing of a sporadic primary immunodeficiency
cohort. Nature. 583:90–95. https://doi.org/10.1038/s41586-020-2265-1
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Supplemental material
Figure S1. PCR strategy to identify the causal SV. (A) PCR primers were designed across breakpoint 1 such that the only possible on-target amplification
occurs in affected individuals. (B) DNA sequence used in PCR primers is shown. dup-inv-dup, duplication-inversion-duplication.
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Figure S2. ANKRD26 duplication-inversion-duplication, not promoter variants, cause ANKRD26 overexpression, leading to a suppression of platelet
signatures and activation of signatures indicative of monocytes. (A) Integrated Genomics Viewer was used to show that affected individuals harbor no
variants in the ANKRD26 promotor, which might explain the thrombocytopenia phenotype. (B) RidgePlot of gene expression profiles of the log2 fold change (FC)
distributions of core genes in the top 20 most significantly enriched gene sets for affected individuals versus unaffected controls. Gene sets were limited to the
biological process ontology. Distributions are colored by gene set enrichment Benjamini-Hochberg-–adjusted P values (p.adjust). (C) Core genes for three
platelet-associated biological processes show consistent downregulation in affected individuals versus unaffected controls. (D) Core genes for the myeloid
leukocyte biological processes show consistent upregulation in affected individuals versus unaffected controls.
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